A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Testosterone Treatment (TTh) Improves Anemia and Hematocrit Increase Reduced Death in Hypogonadal Men: Paradigm Shift of a Risk Factor of TTh
2022
Current Trends in Internal Medicine
Real-life 12 years data show that long-term treatment with testosterone treatment has significant reduction in mortality [1-3] and increase of hematocrit, which theoretically could increase risk of fatal cardiovascular events, could not be proven [4] . Summarizing results of research results that aimed to throw the light on the relationship between hematocrit and all-cause mortality in men receiving TTh in long-term setting [5, 6] .
doi:10.29011/2638-003x.100061
fatcat:nqoopsxhc5hmfexzetkrrnnhrm